These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19888513)

  • 41. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity.
    Fazavana J; Bianchini EP; Saller F; Smadja C; Picard V; Taverna M; Borgel D
    J Thromb Haemost; 2013 Jun; 11(6):1128-36. PubMed ID: 23581397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New trends in anticoagulant therapy.
    Pengo V; Pegoraro C; Iliceto S
    Isr Med Assoc J; 2004 Aug; 6(8):479-81. PubMed ID: 15326828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Idraparinux and liver enzymes: observations from the PERSIST trial.
    Reiter M; Bucek RA; Koca N; Heger J; Minar E;
    Blood Coagul Fibrinolysis; 2003 Jan; 14(1):61-5. PubMed ID: 12544730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis.
    Alame G; Mangin PH; Freund M; Riehl N; Magnenat S; Petitou M; Hechler B; Gachet C
    Thromb Haemost; 2015 Feb; 113(2):385-95. PubMed ID: 25374268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rational design of anticoagulant drugs using oligosaccharide chemistry.
    El Hadri A; Petitou M
    Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.
    Harenberg J; Jörg I; Vukojevic Y; Mikus G; Weiss C
    Eur J Clin Pharmacol; 2008 Jun; 64(6):555-63. PubMed ID: 18283446
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.
    Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    Eur J Clin Pharmacol; 2017 Jan; 73(1):15-28. PubMed ID: 27742998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Idraparinux sodium. Sanofi-Aventis.
    Ma Q; Fareed J
    IDrugs; 2004 Nov; 7(11):1028-34. PubMed ID: 15551178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Efficient Modular One-Pot Synthesis of Heparin-Based Anticoagulant Idraparinux.
    Dey S; Lo HJ; Wong CH
    J Am Chem Soc; 2019 Jul; 141(26):10309-10314. PubMed ID: 31244187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extended Physicochemical Characterization of the Synthetic Anticoagulant Pentasaccharide Fondaparinux Sodium by Quantitative NMR and Single Crystal X-ray Analysis.
    Wildt W; Kooijman H; Funke C; Üstün B; Leika A; Lunenburg M; Kaspersen F; Kellenbach E
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28817073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Modular Synthetic Approach to Isosteric Sulfonic Acid Analogues of the Anticoagulant Pentasaccharide Idraparinux.
    Mező E; Eszenyi D; Varga E; Herczeg M; Borbás A
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Total synthesis of anticoagulant pentasaccharide fondaparinux.
    Li T; Ye H; Cao X; Wang J; Liu Y; Zhou L; Liu Q; Wang W; Shen J; Zhao W; Wang P
    ChemMedChem; 2014 May; 9(5):1071-80. PubMed ID: 24729477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Idraparinux sodium: SANORG 34006, SR 34006.
    Drugs R D; 2004; 5(3):164-5. PubMed ID: 15139779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The design and evaluation of heparin-binding foldamers.
    Choi S; Clements DJ; Pophristic V; Ivanov I; Vemparala S; Bennett JS; Klein ML; Winkler JD; DeGrado WF
    Angew Chem Int Ed Engl; 2005 Oct; 44(41):6685-9. PubMed ID: 16094685
    [No Abstract]   [Full Text] [Related]  

  • 57. [New synthesis of the anticoagulant pentasaccharide idraparinux and preparation of its analogues containing sulfonic acid moieties].
    Herczeg M
    Acta Pharm Hung; 2012; 82(3):113-9. PubMed ID: 23230650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of an intrinsic tenase complex inhibitor: Pure nonasaccharide from fucosylated glycosaminoglycan.
    Zhao L; Wu M; Xiao C; Yang L; Zhou L; Gao N; Li Z; Chen J; Chen J; Liu J; Qin H; Zhao J
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8284-9. PubMed ID: 26100870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemically synthesized heparin-derived oligosaccharides.
    Choay J
    Ann N Y Acad Sci; 1989; 556():61-74. PubMed ID: 2660689
    [No Abstract]   [Full Text] [Related]  

  • 60. Preparation and anticoagulant activity of the phosphosulfomannan PI-88.
    Yu G; Gunay NS; Linhardt RJ; Toida T; Fareed J; Hoppensteadt DA; Shadid H; Ferro V; Li C; Fewings K; Palermo MC; Podger D
    Eur J Med Chem; 2002 Oct; 37(10):783-91. PubMed ID: 12446036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.